Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports.

Lattice Semiconductor (NASDAQ:LSCC – Get Free Report) had its price target boosted by Stifel Nicolaus from $65.00 to $70.00 in a report released on Tuesday,Benzinga reports. The firm presently has a ...

BMO Capital Markets maintained its Outperform rating and $545.00 price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), representing a 16% upside from the current price of $469.97. With a ...

Piper Sandler expressed continued confidence in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), maintaining an Overweight ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

Vertex provided 2025 revenue guidance of $11.75 billion to $12 billion, reflecting 8% growth at the midpoint. Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ...

European shares edged up on Monday but news of US president Donald Trump’s plan to tariff steel and aluminium hit some stocks ...

We recently published an article titled Jim Cramer’s Thoughts On These 8 Stocks and the Packaged Goods Playbook. In this ...

Real-time index price for TSX 60 ESG Index (TSXE), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws.